生化标志物在新型冠状病毒肺炎患者监测中的作用
Role of biochemical markers in the monitoring of COVID-19 patients.
作者信息
Letelier Pablo, Encina Nicole, Morales Pablo, Riffo Alejandra, Silva Halett, Riquelme Ismael, Guzmán Neftalí
机构信息
Universidad Católica de Temuco, Facultad de Ciencias de la Salud, Departamento de Procesos Diagnósticos y Evaluación, Precision Health Research Laboratory, Temuco, Chile.
Universidad Autónoma de Chile, Facultad de Ciencias de la Salud, Instituto de Ciencias Biomédicas, Chile.
出版信息
J Med Biochem. 2021 Mar 12;40(2):115-128. doi: 10.5937/jomb0-29341.
Abstract
COVID-19 is an infectious disease caused by the SARSCoV-2 virus, which has given rise to a global sanitary emergency. The clinical characteristics of COVID-19 are varied and can range from an asymptomatic infection to a mild to severe pneumonia. Recent studies have shown that different laboratory parameters become altered in these patients, and as such are useful as biomarkers to assess the progression of the disease and categorize patients that may present a severe and/or fatal clinical condition. This review analyzes biochemical and immunological markers that become altered in COVID-19 patients and their impact on different organs at a hepatic, cardiac, renal and pancreatic level, as well as markers of inflammation, analyzing their implications in the evolution of the disease.
摘要
新型冠状病毒肺炎（COVID-19）是由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的一种传染病，它已引发了一场全球卫生紧急事件。COVID-19的临床特征多种多样，从无症状感染到轻度至重度肺炎不等。最近的研究表明，这些患者的不同实验室参数会发生改变，因此作为生物标志物有助于评估疾病进展并对可能出现严重和/或致命临床状况的患者进行分类。本综述分析了COVID-19患者体内发生改变的生化和免疫标志物及其在肝脏、心脏、肾脏和胰腺水平对不同器官的影响，以及炎症标志物，并分析了它们在疾病演变中的意义。
相似文献
1
Role of biochemical markers in the monitoring of COVID-19 patients.生化标志物在新型冠状病毒肺炎患者监测中的作用
J Med Biochem. 2021 Mar 12;40(2):115-128. doi: 10.5937/jomb0-29341.
2
Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis.与 2019 年冠状病毒病（COVID-19）严重疾病和死亡相关的血液学、生物化学和免疫生物标志物异常：荟萃分析。
Clin Chem Lab Med. 2020 Jun 25;58(7):1021-1028. doi: 10.1515/cclm-2020-0369.
3
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.评估 BIO101 预防 COVID-19 肺炎患者呼吸恶化的疗效和安全性（COVA 研究）：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5.
4
Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.在医院环境中评估羟氯喹化学预防 SARS-CoV2 感染在医护人员中的疗效和安全性的对照、双盲、随机试验：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):472. doi: 10.1186/s13063-020-04400-4.
5
Host Response to SARS-CoV2 and Emerging Variants in Pre-Existing Liver and Gastrointestinal Diseases.宿主对 SARS-CoV2 及现有肝脏和胃肠道疾病中新兴变异株的反应。
Front Cell Infect Microbiol. 2021 Oct 25;11:753249. doi: 10.3389/fcimb.2021.753249. eCollection 2021.
6
The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.SARS-CoV-2 依维莫司纳瓦拉-ISGlobal 试验（SAINT）评估依维莫司在症状出现后 48 小时内降低低危、非重症 COVID-19 患者 COVID-19 传播风险的潜力：一项随机对照试验方案的研究方案结构化总结。
Trials. 2020 Jun 8;21(1):498. doi: 10.1186/s13063-020-04421-z.
7
Implications of SARS-CoV-2 infection on the clinical, hematological, and inflammatory parameters in COVID-19 patients: A retrospective cross-sectional study.严重急性呼吸综合征冠状病毒 2 感染对 COVID-19 患者临床、血液学和炎症参数的影响：一项回顾性横断面研究。
J Infect Public Health. 2022 Feb;15(2):214-221. doi: 10.1016/j.jiph.2021.12.013. Epub 2022 Jan 6.
8
Mild versus severe COVID-19: Laboratory markers.轻症与重症 COVID-19：实验室标志物。
Int J Infect Dis. 2020 Jun;95:304-307. doi: 10.1016/j.ijid.2020.04.061. Epub 2020 Apr 25.
9
Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial.多臂试验炎症信号抑制剂（MATIS）治疗 COVID-19 轻症或中度肺炎住院患者：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 12;22(1):270. doi: 10.1186/s13063-021-05190-z.
10
Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status.儿童 COVID-19 患者不同严重程度和过敏状态的 182 例临床特征。
Allergy. 2021 Feb;76(2):510-532. doi: 10.1111/all.14452. Epub 2020 Sep 3.
引用本文的文献
1
Gender differences in correlation of biochemical parameters with the severity of covid pneumonia and the need for oxygen/mechanical support.新冠肺炎严重程度与生化参数的相关性以及对氧气/机械通气支持需求方面的性别差异。
J Med Biochem. 2025 Mar 21;44(2):250-255. doi: 10.5937/jomb0-49377.
2
Lifestyle and Biochemical Parameters That May Hamper Immune Responses in Pediatric Patients After Immunization with the BNT162b2 mRNA COVID-19 Vaccine.可能妨碍儿科患者接种BNT162b2 mRNA新冠疫苗后免疫反应的生活方式和生化参数
Diseases. 2025 Mar 10;13(3):78. doi: 10.3390/diseases13030078.
3
The Impact of Vaccination on COVID-19 Outcomes in Vietnam.疫苗接种对越南新冠疫情结局的影响
Diagnostics (Basel). 2024 Dec 18;14(24):2850. doi: 10.3390/diagnostics14242850.
4
Smoking and Health Profiles of Hypertensive Patients with COVID-19: An Exploratory Study of Key Physiological Markers.新冠病毒肺炎高血压患者的吸烟情况与健康状况：关键生理标志物的探索性研究
J Clin Med. 2024 Nov 28;13(23):7245. doi: 10.3390/jcm13237245.
5
Dynamic changes of hematological and hemostatic parameters in COVID-19 hospitalized patients: Potential role as severity biomarkers for the Chilean population.新冠病毒肺炎住院患者血液学和止血参数的动态变化：对智利人群作为疾病严重程度生物标志物的潜在作用
J Med Biochem. 2024 Jun 15;43(4):556-564. doi: 10.5937/jomb0-47588.
6
Evaluation of Biochemical Characteristics in a Retrospective Cohort of COVID-19 Patients.COVID-19患者回顾性队列中的生化特征评估
Cureus. 2024 Apr 24;16(4):e58889. doi: 10.7759/cureus.58889. eCollection 2024 Apr.
7
Mathematical model of aging in COVID-19.新冠病毒感染中衰老的数学模型
J Med Biochem. 2023 Aug 25;42(3):383-391. doi: 10.5937/jomb0-39602.
8
Prognostic values of baseline cortisol levels and neutrophil to lymphocyte ratio in COVID-19.新冠病毒病中基线皮质醇水平及中性粒细胞与淋巴细胞比值的预后价值
J Med Biochem. 2023 Aug 25;42(3):437-443. doi: 10.5937/jomb0-38533.
9
The utility of serum amyloid A and other acute-phase reactants determination in ambulatory care COVID-19 patients.血清淀粉样蛋白A及其他急性期反应物测定在门诊COVID-19患者中的应用
J Med Biochem. 2023 Aug 25;42(3):492-504. doi: 10.5937/jomb0-42799.
10
The predictive role of biochemical markers on outcomes of severe COVID-19 patients admitted to intensive care unit.生化标志物对入住重症监护病房的重症 COVID-19 患者预后的预测作用。
J Med Biochem. 2023 Aug 25;42(3):513-523. doi: 10.5937/jomb0-40641.
本文引用的文献
1
Urinalysis, but Not Blood Biochemistry, Detects the Early Renal Impairment in Patients with COVID-19.尿液分析而非血液生化检测可发现新冠病毒感染患者的早期肾功能损害。
Diagnostics (Basel). 2022 Feb 27;12(3):602. doi: 10.3390/diagnostics12030602.
2
Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection.人类肾脏是新型严重急性呼吸综合征冠状病毒 2 感染的靶器官。
Nat Commun. 2021 May 4;12(1):2506. doi: 10.1038/s41467-021-22781-1.
3
Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19: a retrospective study.新型冠状病毒肺炎患者疾病严重程度与炎症相关参数的相关性分析：一项回顾性研究。
BMC Infect Dis. 2020 Dec 21;20(1):963. doi: 10.1186/s12879-020-05681-5.
4
C-reactive protein as an early predictor of COVID-19 severity.C反应蛋白作为新冠病毒疾病严重程度的早期预测指标
J Med Biochem. 2020 Oct 2;39(4):500-507. doi: 10.5937/jomb0-27554.
5
Pharmacogenomics landscape of COVID-19 therapy response in Serbian population and comparison with worldwide populations.塞尔维亚人群中新冠病毒疾病治疗反应的药物基因组学概况及与全球人群的比较。
J Med Biochem. 2020 Oct 2;39(4):488-499. doi: 10.5937/jomb0-26725.
6
IFCC Interim Guidelines on Biochemical/Hematological Monitoring of COVID-19 Patients.IFCC 临时指南：COVID-19 患者的生化/血液学监测。
Clin Chem Lab Med. 2020 Oct 7;58(12):2009-2016. doi: 10.1515/cclm-2020-1414.
7
Apparent difference in fatalities between Central Europe and East Asia due to SARS-COV-2 and COVID-19: Four hypotheses for possible explanation.由于 SARS-CoV-2 和 COVID-19，中欧和东亚的死亡率存在明显差异：可能解释的四个假设。
Med Hypotheses. 2020 Nov;144:110160. doi: 10.1016/j.mehy.2020.110160. Epub 2020 Aug 5.
8
Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19).COVID-19 患者近期康复后的心血管磁共振成像结果。
JAMA Cardiol. 2020 Nov 1;5(11):1265-1273. doi: 10.1001/jamacardio.2020.3557.
9
Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of COVID-19 Infection.超高通量临床蛋白质组学揭示 COVID-19 感染的分类器。
Cell Syst. 2020 Jul 22;11(1):11-24.e4. doi: 10.1016/j.cels.2020.05.012. Epub 2020 Jun 2.
10
Molecular and Serological Tests for COVID-19 a Comparative Review of SARS-CoV-2 Coronavirus Laboratory and Point-of-Care Diagnostics.新型冠状病毒肺炎的分子和血清学检测：严重急性呼吸综合征冠状病毒2实验室诊断与即时检测的比较综述
Diagnostics (Basel). 2020 Jun 26;10(6):434. doi: 10.3390/diagnostics10060434.
Zotero 插件